文献速递心外重症与机械循环支持

更新版ISHLT严重移植物功能障碍定义的预后意义:国际PGD联盟与UNOS数据库分析

Prognostic implications of the updated ISHLT definition for severe graft dysfunction: An analysis from the International PGD Consortium and UNOS Databases.
PubMed 文献 · J Heart Lung Transplant · 2026-06-09

本研究基于国际PGD联盟和UNOS注册数据,评估2024年ISHLT共识将心脏移植后24小时内新置IABP纳入严重移植物功能障碍定义对预后的影响。结果显示,新置IABP患者1年死亡率显著低于2014标准严重PGD患者,更接近无严重PGD者,提示将两类人群合并可能掩盖预后差异。

要点

  • 新置IABP患者1年死亡率低于2014标准严重PGD患者,接近无严重PGD者。
  • 2024标准重新分类的IABP患者1年死亡风险显著低于2014标准严重PGD患者。
  • 将IABP与ECMO/VAD依赖者合并可能削弱对最严重PGD表型的识别。

核心结论

  • 心脏移植后24小时内新置IABP患者的生存率显著优于ECMO或VAD依赖者。
  • 将不同预后的人群合并入新的严重PGD定义可能掩盖预后差异。

研究设计与样本

  • 基于国际PGD联盟(4087例)和UNOS(3152例)注册数据的回顾性队列分析,共纳入7239例心脏移植受者。
  • 按2014标准严重PGD、2024标准新置IABP重新分类为严重EGD、无严重PGD三组比较。

主要发现

  • 联盟队列中三组分别为361例(8.8%)、116例(2.8%)、3610例(88.3%)。
  • 1年死亡率:新置IABP组联盟12.1%、UNOS 9.6%;2014标准严重PGD组联盟36.3%、UNOS 27.2%;无严重PGD组联盟7.4%、UNOS 5.6%(Log-rank p<0.001)。
  • 联盟队列多因素校正后,新置IABP组1年死亡HR 0.30(0.17-0.51),无严重PGD组HR 0.17(0.14-0.22),均低于2014标准严重PGD组(P<0.001)。
  • UNOS人群重复了上述发现。

关键数值与推荐

  • 2024 ISHLT共识将心脏移植后24小时内新置IABP纳入严重移植物功能障碍诊断标准。
  • 2014标准严重PGD组1年死亡率联盟36.3%、UNOS 27.2%。
  • 新置IABP组1年死亡率联盟12.1%、UNOS 9.6%。
  • 无严重PGD组1年死亡率联盟7.4%、UNOS 5.6%。

临床怎么用

  • 临床评估心脏移植后严重PGD时应区分IABP依赖与ECMO/VAD依赖,二者预后差异显著。
  • 新置IABP患者预后接近无严重PGD者,不宜与ECMO/VAD依赖者等同管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The proposed 2024 ISHLT consensus definition for severe graft dysfunction after heart transplant (HT) expands the 2014 criteria by including de novo intra-aortic balloon pump (IABP) support as diagnostic for severe dysfunction. We evaluated the prognostic implications of this reclassification using data from the International Consortium on PGD (herein 'Consortium') and United Network for Organ Sharing (UNOS) registries. METHODS: Heart Transplant (HT) recipients were categorized into the following groups (1) meeting 2014 severe PGD criteria, (2) reclassified as severe early graft dysfunction (EGD) by the 2024 criteria based on a newly placed IABP within 24 h of HT, or (3) not meeting severe PGD criteria. KM survival curves and log-rank tests were used to compare unadjusted survival. A multivariable Cox regression model was used to determine the association of group status on 1 year mortality. RESULTS: A total of 7239 HT recipients with relevant data were included in this analysis: 4087 in the Consortium and 3152 from UNOS. In the Consortium cohort, 361 (8.8%), 116 (2.8%), and 3610 (88.3%) patients comprised Groups 1, 2 and 3, respectively. Group 1 had more pre-transplant temporary and durable mechanical circulatory support, along with longer ischemic times. At 1 year post-HT, mortality in patients with de novo IABP (12.1% in Consortium, 9.6% in UNOS) was significantly lower than in patients with 2014 severe PGD (36.3% in Consortium, 27.2% in UNOS), and more closely resembled those without severe PGD (7.4% in Consortium, 5.6% in UNOS) [Log-rank p < 0.001 in both groups]. After adjustment for potential confounders, both reclassified patients with a de novo IABP [Group 2: HR 0.30 (0.17-0.51)] and patients without severe PGD [Group 3: HR 0.17 (0.14-0.22)] had significantly reduced risk of 1 year mortality compared to those with 2014 severe PGD (P<0.001) in the Consortium. These findings were replicated in the UNOS population. CONCLUSION: In this analysis of two contemporary, multicentre databases, patients who received an isolated de novo IABP within the first 24 h postoperatively had significantly better survival than those who were dependent on extra-corporeal membrane oxygenation (ECMO) or ventricular assist devices after HT. Combining these disparate patient groups in the new severe PGD definition may obscure prognostic differences and diminish recognition of the most severe PGD phenotype.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Dhingra NK, Devore AD, Hall SA, et al. Prognostic implications of the updated ISHLT definition for severe graft dysfunction: An analysis from the International PGD Consortium and UNOS Databases. J Heart Lung Transplant. 2026. PMID: 42263895. doi:10.1016/j.healun.2026.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。